CHS-1000, an Innovative ILT4 Antagonist Antibody, Showcased Through Early-Stage Research at AACR's 2024 Gathering.

Vivet Therapeutics Administers Initial Dose to First Participant in Second Group of Phase 1/2 GATEWAY Study for Wilson Disease Therapy.

Up to now, at the AACR meeting, updates on the clinical progress of several ADC drugs have been presented, involving targets such as HER2, BCMA, CD123, FRα, CCR7, Axl, etc.

Promising Early Results for SCB-1019 Vaccine in Young Adults: Clover Biopharmaceuticals Phase I Insights.

The high failure rate of clinical trials, often cited to be around 90%, can be attributed to several factors.

Ichnos Glenmark Innovation Unveils Early Findings for Cancer Candidate ISB 2001 at AACR 2024.

The failure of clinical trials can stem from multiple factors. One study suggests that 90% of drug development clinical failures may be attributed to four reasons: lack of clinical efficacy (40%-50%), uncontrollable toxicity (30%), poor pharmacokinetic properties (10%-15%), and absence of commercial demand or poor strategic planning (10%).

Mabwell has declared that its fully-owned subsidiary, T-mab, has successfully received the green light for its Denosumab Injection from the National Medical Products Administration.

As the potential of molecular glue technology becomes increasingly apparent, pharmaceutical companies are beginning to invest more heavily in this area.

Primary Objectives Achieved in Stage 3 Trial for HLX14, a Biosimilar Contender to Prolia® and Xgeva® (denosumab).

April 11th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Ferring Unveils Key Phase 3 Results for Experimental Therapy, SI-6603 (condoliase), in Treating Lower Back Disc Protrusion during ASIPP 2024.